How synthetic oligos can be used as a convenient and reliable RNA source for your experiment.
Design and performance implications of miRNA tools in vivo.
CRISPR-Cas9 lentiviral sgRNA pooled screening changes everything.
Mice continue to play a significant role in all facets of molecular research!
Every year since 2007, The Scientist Magazine gets hundreds (thousands?) of nominations for their Top 10 Innovations Award.
Pre-arrayed gene families of expression-ready ORFs
Extra measures to ensure we provide you with a viable glycerol stock of your clone!
Now SMARTCas9 gives you a CHOICE of promoters for optimal Cas9 expression in your specific cells.
Ordering guidelines for quantities of crRNA and tracrRNA
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.